ClinicalTrials.gg

Program

Recombinant Super-compound Interferon

Also written as “rSIFN-co Nasal Spray”, “rSIFN-co” and “Recombinant Super-Compound Interferon (rSIFN-co)”.

Its studies are mostly in Rectal Neoplasms · COVID-19 · Neuroendocrine Tumors · Carcinoma, Non-Small-Cell Lung, led by Sichuan Huiyang Life Science and Technology.

Furthest: phase 2, since Jun 16, 20224 company-led studies, 1 open or runningNext primary completion: Jan 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Huiyang Life Science and Technology41 open or runningphase 2since Jun 16, 2022Feb 6, 2015Jan 2030phase 2 · NCT07662278

Also a collaborator on its studies: medelis-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 6, 2015First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT02387307 · 42 enrolled · Singapore
  2. Jun 3, 2015Phase 1 study in Neuroendocrine TumorsNCT02464007 · 7 enrolled · United States
  3. Jun 16, 2022Phase 2 study in COVID-19NCT05485584 · 188 enrolled · Philippines
  4. Jun 16, 2026Phase 2 study in Mid-low Locally Advanced Rectal CancerNCT07662278 · 90 planned

Ahead

  1. Jan 2030Primary completion: phase 2 study in Mid-low Locally Advanced Rectal CancerNCT07662278

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07662278Mid-low Locally Advanced Rectal Cancer2Not yet recruitingJan 203090
NCT05485584COVID-19 · Philippines2CompletedApr 5, 2023188
NCT02464007Neuroendocrine Tumors · United States1TerminatedNov 20247
NCT02387307Carcinoma, Non-Small-Cell Lung · Singapore1CompletedJun 201842

How it is read

Names in the registry

  • “rSIFN-co Nasal Spray”, 2 entries
  • “rSIFN-co”, 2 entries
  • “Recombinant Super-Compound Interferon (rSIFN-co)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.